Diabetes and well-being is the theme for World Diabetes Day 2024-26.
On November 14th, we join the global community in recognizing World Diabetes Day, a day dedicated to raising awareness about the impact of diabetes worldwide. Led by the International Diabetes Federation (IDF), World Diabetes Day emphasizes the importance of education, early diagnosis, and access to effective treatments for over 500 million people worldwide currently living with diabetes.
At Tiefenbacher Group, we are committed to making a difference by providing more affordable, more available, and better therapies to improve the life of people affected by diabetes. Our portfolio includes pharmaceuticals like Vildagliptin, which is available as monotherapy and in combination with Metformin. Vildagliptin is a DPP-4 inhibitor, which helps to improve blood sugar control in adults with type 2 diabetes by enhancing the body’s natural regulation of insulin and glucose.
On World Diabetes Day, we stand with patients, their relatives, and healthcare providers in the fight against diabetes. Together, we strive for a future where everyone has access to the care and resources they need.
Contact us:
In case of inquiries please reach out to licensing@tiefenbacher.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
